About OZURDEX®
Placeholder only.
To be populated with localised
resources. Please see the AbbVie Pro
asset grid in attachments for details
of the resources to be localised
Patient materials
Placeholder only.
To be populated with localised
resources. Please see the AbbVie Pro
asset grid in attachments for details
of the resources to be localised
Role of inflammation in DME
Placeholder only.
To be populated with localised
resources. Please see the AbbVie Pro
asset grid in attachments for details
of the resources to be localised
Clinic resources
Placeholder only.
To be populated with localised
resources. Please see the AbbVie Pro
asset grid in attachments for details
of the resources to be localised
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently
responsive to, or unsuitable for non-corticosteroid therapy - Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220126. Date of Preparation April 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.